US FDA explores letting pharma call dibs on drug names
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is considering the proposal for drug makers to reserve proprietary names of medicines – an idea that has been kicked around since industry raised it during the negotiations process for the fourth round of the Prescription Drug User Fee Act in 20071.